Monday, November 3, 2025

Kula Bio Finalizes Series A-1 Funding Round and Announces Executive Leadership Transitions

Kula Bio secures Series A-1 funding and announces key leadership transitions to drive the next phase of growth in sustainable nitrogen technology.

As global demand for regenerative agriculture solutions continues to surge, Kula Bio is positioned to lead the transition toward more sustainable and efficient farming practices.”
— Harrison Yoon, CEO

NATICK, MA, UNITED STATES, November 3, 2025 /EINPresswire.com/ -- Kula Bio, a leading innovator in sustainable nitrogen solutions, today announced the successful close of its Series A-1 funding round. The funding underscores strong investor confidence in Kula Bio’s mission to transform agriculture through advanced biotechnology. The new capital will accelerate Kula Bio’s commercial expansion and support continued innovation in its proprietary microbial nitrogen platform.

In conjunction with this milestone, Kula Bio is implementing strategic executive leadership

First Patient Treated with BioVentrix® Revivent System in RELIVE Trial at Saint Luke’s Mid America Heart Institute

BioVentrix Logo

BioVentrix, Inc.

Pivotal RELIVE Trial Is Evaluating the Safety and Efficacy of BioVentrix’s Revivent System in the Treatment of Patients Who Have Experienced Heart Failure

For the right patient, treatment with the Revivent System could represents a valuable option. This approach offers a remarkably straightforward solution to a complex problem.”
— Andrew Kao, MD, advanced heart failure cardiologist.

MANSFIELD, MA, UNITED STATES, November 3, 2025 /EINPresswire.com/ -- BioVentrix, Inc., a private clinical-stage medical device company specializing in left ventricular function restoration following heart failure, today announced the completion of treatment of its first patient in its pivotal RELIVE (Randomized Evaluation of Less Invasive Ventricular Enhancement) clinical trial at Saint Luke’s Mid America Heart Institute in Kansas City, Missouri.

BioVentrix’s proprietary Revivent System, which is being studied in the RELIVE trial, is

The Human Revolution in the AI Age: Why Empowerment, Not Automation, Is the Future

AI won’t replace people—it equips them. Edge-native design builds privacy, speed, consent into daily habits; next: agentic execution with humans in command.

The enduring story of AI isn't displacement—it's enablement.”
— Mark Johnson, COO of mEinstein

BOSTON, MA, UNITED STATES, November 3, 2025 /EINPresswire.com/ -- The first era of mainstream AI proved that machines can generate and infer at scale. The second era will prove something more consequential: people thrive when AI is designed for empowerment, not replacement. Empowerment is not an abstraction; it is a product choice—how and where intelligence runs, who controls consent, and who benefits when value changes hands.

mEinstein advances an agency-first thesis. Rather than minimizing human involvement, the

Sunday, November 2, 2025

Cummings Foundation and Massachusetts School of Law Present “Good Business Practices & Preventing Problem Employees”

Massachusetts School of Law

Andover, Massachusetts – The Cummings Foundation, in collaboration with the Massachusetts School of Law (MSLAW), proudly announces the return of its free public seminar series designed to help local business owners, entrepreneurs, and professionals strengthen their operations through sound legal and management strategies.

The Fall 2025 session, titled “Good Business Practices & Preventing Problem Employees,” will take place on Tuesday, November 12, from 5:15 p.m. to 7:15 p.m. at the

LEDVANCE Expands PHASE EV™ Lineup with New 80 amp Level 2 Commercial Charger


A powerful evolution in EV infrastructure, bringing together speed, strength, and scalability for the next era of commercial charging.

WILMINGTON, Mass., Nov. 01, 2025 (GLOBE NEWSWIRE) -- LEDVANCE, a global leader in lighting and energy solutions, today announced the North American availability of its new PHASE EV™ 80 Amp Level 2 Commercial Charger, the latest evolution in its growing EVSE portfolio. Building on the success of the PHASE EV™ Gen 2 (48 amp) release earlier this year, the new 80 amp model delivers nearly 20 kW of output power, offering faster, smarter, and more flexible charging for fleet, workplace, and multi-unit residential environments.

“The 80 amp model represents the next leap forward for LEDVANCE as we expand into

Real Estate Expert Serena LoPiccolo-Smith of Falmouth, MA Explains What Makes Falmouth a Hidden Gem for Luxury Buyers for HelloNation

FALMOUTH, Mass., Nov. 02, 2025 (GLOBE NEWSWIRE) -- What makes Falmouth real estate such a draw for those seeking refined yet peaceful coastal living? A recent HelloNation article reveals why this Cape Cod town has become one of the most desirable destinations for luxury buyers who want elegance without the crowds.

The article highlights how Falmouth real estate has quietly earned its reputation among

Saturday, November 1, 2025

NCC-Bio and GR Boston N. Announce Breakthrough in Overcoming KRAS Therapy Resistance, Pancreatic Cancer Awareness Month

KN510713 is the only available drug for FAO inhibition in Oncology Phase II Trial in the World. There is no severe adverse effect of KN510/713 during Ph I study.

KRAS inhibition alongside FAO inhibition (KN510713) leads to the ‘Cell Death Storm’

Breakthrough in Overcoming KRAS Therapy Resistance During Pancreatic Cancer Awareness Month, November 2025.

Together, we can make this the month the world learns how to turn resistance into response for pancreatic cancer.”
— Warren Park

BOSTON, MA, UNITED STATES, November 1, 2025 /EINPresswire.com/ -- ________________________________________
NCC-Bio and Global Bio Match Service Announce Breakthrough in Overcoming KRAS Therapy Resistance During Pancreatic Cancer Awareness Month

In recognition of Pancreatic Cancer Awareness Month, NCC-Bio (National Cancer Center Bio Co., Ltd.) and Global Bio Match Service (GBMS) announced new findings from their joint